FindTrial
Sign In

Placebo (for sarilumab)

DRUG5 trials

Sponsors

Sanofi

Conditions

Rheumatoid ArthritisUveitis

Phase 2

Evaluation of Sarilumab (SAR153191/REGN88) on Top of Methotrexate in Rheumatoid Arthritis Patients
CompletedNCT01061736
SanofiRheumatoid Arthritis
Start: 2010-03-31End: 2013-10-31Updated: 2017-06-28
Phase II Study to Analyze Sarilumab in Non-Infectious Uveitis
CompletedNCT01900431
SanofiUveitis
Start: 2013-10-31End: 2016-04-30Updated: 2017-06-20

Phase 3

An Evaluation of Sarilumab Plus Methotrexate Compared to Etanercept Plus Methotrexate in RA Patients Not Responding to Adalimumab Plus Methotrexate
TerminatedNCT01764997
SanofiRheumatoid Arthritis
Start: 2013-04-30End: 2015-01-31Updated: 2017-07-27
A Study Assessing the Efficacy and Safety of Sarilumab Added to MTX in Japanese Patients With Moderately to Severely Active Rheumatoid Arthritis (SARIL-RA-KAKEHASI)
CompletedNCT02293902
SanofiRheumatoid Arthritis
Start: 2014-11-30End: 2016-10-31Updated: 2018-01-30
Efficacy and Safety of Sarilumab and Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (SARIL-RA-MONARCH)
CompletedNCT02332590
SanofiRheumatoid Arthritis
Start: 2015-01-28End: 2020-12-29Updated: 2022-03-28

Related Papers

Deciphering differential biomarkers for anti-interleukin-6 receptor and anti-tumour necrosis factor-α treatment response in rheumatoid arthritis by multiomics analysis
RMD Open2025-07-011 citations
Efficacy and safety of sarilumab in patients with rheumatoid arthritis stratified by age (&amp;lt;65 and ≥65 years): A <i>post hoc</i> analysis of Japanese Phase 3 clinical trials
Modern Rheumatology2024-07-282 citations
Long-term safety and efficacy of sarilumab with or without background csDMARDs in rheumatoid arthritis
Lara D. Veeken2023-02-0211 citations
Disproportionate articular pain is a frequent phenomenon in rheumatoid arthritis and responds to treatment with sarilumab
Lara D. Veeken2022-11-2117 citations
Haemoglobin changes and disease activity in Japanese patients with rheumatoid arthritis treated with sarilumab.
2022-10-281 citations
Association between low hemoglobin, clinical measures, and patient-reported outcomes in patients with rheumatoid arthritis: results from post hoc analyses of three phase III trials of sarilumab
Arthritis Research & Therapy2022-08-257 citations
Identification of a Rule to Predict Response to Sarilumab in Patients with Rheumatoid Arthritis Using Machine Learning and Clinical Trial Data
Rheumatology and Therapy2021-09-1423 citations
Population Pharmacokinetic-Pharmacodynamic Relationships of Sarilumab Using Disease Activity Score 28-Joint C-Reactive Protein and Absolute Neutrophil Counts in Patients with Rheumatoid Arthritis.
2020-11-014 citations
High levels of interleukin-6 in patients with rheumatoid arthritis are associated with greater improvements in health-related quality of life for sarilumab compared with adalimumab.
2020-10-2028 citations
Interleukin-6 receptor blockade or TNFα inhibition for reducing glycaemia in patients with RA and diabetes: post hoc analyses of three randomised, controlled trials.
2020-09-0923 citations
Association of High Serum Interleukin-6 Levels With Severe Progression of Rheumatoid Arthritis and Increased Treatment Response Differentiating Sarilumab From Adalimumab or Methotrexate in a Post Hoc Analysis.
2020-08-2533 citations
Efficacy and safety of sarilumab in combination with csDMARDs or as monotherapy in subpopulations of patients with moderately to severely active rheumatoid arthritis in three phase III randomized, controlled studies.
2020-06-1020 citations
Sarilumab and adalimumab differential effects on bone remodelling and cardiovascular risk biomarkers, and predictions of treatment outcomes.
2020-04-0731 citations
EP25 Impact of sarilumab on unacceptable pain and inflammation control in moderately-to-severely active rheumatoid arthritis (RA) patients in 3 Phase 3 studies
Lara D. Veeken2020-04-011 citations
P213 High baseline serum IL-6 predicts increased sarilumab treatment response for patient reported symptoms and health-related quality of life among RA patients with inadequate response to MTX
Lara D. Veeken2020-04-01
P235 Glucocorticoid dose is progressively reduced in Patients with rheumatoid arthritis (RA) receiving sarilumab: results from the open label EXTEND study
Lara D. Veeken2020-04-01
Safety and efficacy of switching from adalimumab to sarilumab in patients with rheumatoid arthritis in the ongoing MONARCH open-label extension
RMD Open2019-10-0113 citations
Long-term safety and efficacy of sarilumab plus methotrexate on disease activity, physical function and radiographic progression: 5 years of sarilumab plus methotrexate treatment
RMD Open2019-08-0138 citations
Immunogenicity of Sarilumab Monotherapy in Patients with Rheumatoid Arthritis Who Were Inadequate Responders or Intolerant to Disease-Modifying Antirheumatic Drugs.
2019-05-1424 citations
Economic Evaluation of Sarilumab in the Treatment of Adult Patients with Moderately-to-Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic Disease-Modifying Antirheumatic Drugs.
2019-04-195 citations

11 more papers not shown